Treatment Action Group

Public investment in bedaquiline up to five-fold that of Johnson & Johnson

PLOS ONE publishes TAG’s rigorous, peer-reviewed calculation of investments in the development of this life-saving TB medicine.

Read More →

TAG policy brief: TB Research Investments Provide Returns in Combating Both TB and COVID-19

Sustained and expanded financing is needed to safeguard TB research against COVID-19–related disruptions and improve global epidemic preparedness.

Read More →

Letter to Sanofi calling for patent withdrawals on critical TB drugs

TAG and OTMeds call on Sanofi to reverse its efforts to patent two obvious combinations of two critical drugs to prevent TB: rifapentine and isoniazid.

Read More →

TAG launches two new TB Activist Guides

Treatment Action Group launches two new TB Activist Guides: An Activist’s Guide to Tuberculosis Diagnostic Tools, and An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis.

Read More →

Treatment Action Group statement on bedaquiline unaffordability

Bedaquiline is a public good, and must be treated as such. Johnson & Johnson once again refused to meet evidence-based demands to price bedaquiline at $1/day.

Read More →

TAGline May 2020: Realizing the Right to Science

Treatment Action Group released the May 2020 edition of TAGline, focused on the right to science.

Read More →

Global health and human rights organizations denounce Trump Administration decision to pull commitments to WHO during COVID-19 crisis

Cutting global health funding in the middle of a pandemic will only prolong the devastating loss of life and economic damage in the U.S. and across the world, and undermine the response to other infectious diseases, including HIV, TB, and hepatitis C.

Read More →

TAG statement on BCG vaccine and COVID-19

More research required to determine if century-old TB vaccine protects against SARS-CoV-2 infection or severe COVID-19 disease.

Read More →

Webinar recording: Fair pricing for Cepheid Xpert tests (COVID-19, HIV, TB, HCV)

On 3 April 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, HIV, TB, HCV and other diseases. The webinar provided the latest information about the “Time for $5” campaign and the evidence base for why GeneXpert tests should be priced at US$5.

Read More →

TAG statement on the high price of Cepheid’s Xpert test for COVID-19

Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems.

Read More →

Page 1 of 16 · Total posts: 10

1 2 Last→